DDInter740 DDInter1668
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Siltuximab
Flecainide {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is upregulated by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Siltuximab
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Norethisterone
Norethisterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Siltuximab
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Propafenone
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Siltuximab
Flecainide {u} (Compound) causes {v} (Side Effect) Abnormal dreams
Abnormal dreams {u} (Side Effect) is caused by {v} (Compound) Propafenone
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Siltuximab
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Siltuximab
Flecainide {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Siltuximab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Oliceridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Siltuximab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propafenone
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Siltuximab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Siltuximab
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Flecainide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Flecainide (Compound) causes Abnormal dreams (Side Effect) and Abnormal dreams (Side Effect) is caused by Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Siltuximab
Flecainide (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Siltuximab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab